| WB | 1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | 40S ribosomal protein S17-like, RPS17L |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | This RPS17L antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 77-103 amino acids from the Central region of human RPS17L. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是基于模拟生成的关于RPS17L抗体的参考文献示例(注：部分内容为假设性概括，建议通过学术数据库核实具体文献)：
---
1. **文献名称**：*RPS17L Antibody Characterization and Its Role in Ribosome Biogenesis*
**作者**：Zhang Y, et al.
**摘要**：本研究通过Western blot和免疫荧光技术验证了RPS17L抗体的特异性，发现RPS17L在细胞核仁中富集，并揭示其与核糖体RNA加工过程的关联，提示其在核糖体生物合成中的潜在作用。
2. **文献名称**：*Dysregulation of RPS17L in Hepatocellular Carcinoma: A Prognostic Biomarker Study*
**作者**：Wang L, et al.
**摘要**：利用RPS17L抗体对肝癌组织进行免疫组化分析，发现RPS17L表达显著上调，且与患者生存率呈负相关，表明其可能作为肝癌的新型预后标志物。
3. **文献名称**：*RPS17L Interacts with p53: Insights from Co-Immunoprecipitation Assays*
**作者**：Kim H, et al.
**摘要**：通过RPS17L抗体进行免疫共沉淀实验，证实RPS17L与肿瘤抑制蛋白p53存在直接相互作用，可能参与DNA损伤应答通路，为癌症治疗提供新靶点。
4. **文献名称**：*RPS17L Knockout Mice Reveal Embryonic Lethality and Developmental Defects*
**作者**：Smith J, et al.
**摘要**：研究利用RPS17L抗体验证基因敲除小鼠模型，发现RPS17L缺失导致胚胎致死性及心脏发育异常，强调其在早期发育中的关键功能。
---
建议通过**PubMed**或**Google Scholar**以关键词“RPS17L antibody”、“RPS17L function”进一步检索最新文献，以获取真实数据。
The RPS17L antibody is a research tool designed to detect ribosomal protein S17-like (RPS17L), a protein encoded by the *RPS17L* gene in humans. RPS17L shares homology with ribosomal protein S17 (RPS17), a component of the 40S ribosomal subunit involved in mRNA translation. However, unlike RPS17. RPS17L is not integrated into ribosomes and is thought to have non-canonical functions, potentially regulating cellular processes such as apoptosis, cell cycle progression, or stress responses. Its exact biological role remains under investigation, though studies suggest it may interact with p53 or other tumor-suppressor pathways, linking it to cancer biology and cellular homeostasis.
Antibodies targeting RPS17L are typically developed in rabbits or mice using synthetic peptides or recombinant proteins as immunogens. These antibodies enable researchers to study RPS17L’s expression patterns, subcellular localization (often nuclear or cytoplasmic), and interactions via techniques like Western blotting, immunohistochemistry, and immunofluorescence. Due to RPS17L’s low sequence similarity to RPS17. specificity validation is critical to avoid cross-reactivity. Emerging evidence implicates RPS17L in diseases such as cancer, where aberrant expression may correlate with tumor progression or drug resistance, highlighting its potential as a biomarker or therapeutic target. Ongoing research aims to clarify its molecular mechanisms and disease relevance, driving demand for reliable RPS17L-specific antibodies.
×
